drug eluting stent market size, share, growth drivers, trends, opportunities & forecast 2025–2030
Description
Drug Eluting Stent Market Overview
The Drug Eluting Stent market is valued at USD 8.8 billion, based on a five-year historical analysis. Growth is primarily driven by the increasing prevalence of cardiovascular diseases, advancements in stent technology such as next-generation drug coatings, and rising healthcare expenditure. The demand for drug-eluting stents is further fueled by the growing aging population, the adoption of minimally invasive procedures, and the integration of advanced materials that improve patient outcomes and reduce hospital stays .
Key players in this market are predominantly located in North America, Europe, and Asia-Pacific. The United States leads the market due to its advanced healthcare infrastructure, high prevalence of coronary artery diseases, and significant investments in medical technology. Countries such as Germany and Japan also contribute significantly, driven by robust healthcare systems, high procedure volumes, and ongoing innovation in cardiovascular treatments .
The "Premarket Approval (PMA) for Drug-Eluting Stents: Guidance for Industry and FDA Staff" issued by the U.S. Food and Drug Administration (FDA) in 2023 requires manufacturers to submit enhanced clinical data for approval. This regulation mandates comprehensive evidence of long-term safety and efficacy, including robust data on clinical outcomes and potential risks, as a prerequisite for market entry in the United States .
Drug Eluting Stent Market Segmentation
By Type:
The Drug Eluting Stent market can be segmented into Polymer-Based Drug Eluting Stents, Polymer-Free Drug Eluting Stents, Bioresorbable Stents, Bare Metal Stents, and Others. Polymer-Based Drug Eluting Stents dominate the market due to their demonstrated efficacy in reducing restenosis rates and their widespread clinical acceptance. The preference for these stents is reinforced by their ability to deliver drugs effectively, compatibility with a
oad range of patient profiles, and ongoing innovation in polymer and drug technologies .
By End-User:
The market is also segmented by end-users, including Hospitals, Specialty Clinics, Cardiac Catheterization Labs, Ambulatory Surgical Centers, and Others. Hospitals are the leading end-user segment, attributed to their comprehensive cardiac care capabilities, advanced surgical infrastructure, and the high volume of interventional cardiology procedures performed. The increasing number of percutaneous coronary interventions in hospitals, supported by skilled healthcare professionals and integrated care pathways, continues to drive demand for drug-eluting stents in this segment .
Drug Eluting Stent Market Competitive Landscape
The Drug Eluting Stent Market is characterized by a dynamic mix of regional and international players. Leading participants such as Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Johnson & Johnson (Cordis), B.
aun Melsungen AG, Terumo Corporation, Cook Medical, Cardinal Health, Inc., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Stryker Corporation, Asahi Intecc Co., Ltd., Koninklijke Philips N.V., Biotronik SE & Co. KG, Lepu Medical Technology Co., Ltd., OrbusNeich Medical Group Holdings Limited, Becton, Dickinson and Company contribute to innovation, geographic expansion, and service delivery in this space.
Abbott Laboratories
1888
Abbott Park, Illinois, USA
Boston Scientific Corporation
1979
Marlborough, Massachusetts, USA
Medtronic plc
1949
Dublin, Ireland
Johnson & Johnson (Cordis)
1886
New
unswick, New Jersey, USA
B.
aun Melsungen AG
1839
Melsungen, Germany
Company
Establishment Year
Headquarters
Group Size (Large, Medium, or Small as per industry convention)
Global Drug Eluting Stent Revenue
Revenue Growth Rate (CAGR)
Market Share (%)
Geographic Presence (Number of Countries/Regions)
Product Portfolio
eadth (Number of DES SKUs)
Drug Eluting Stent Market Industry Analysis
Growth Drivers
Increasing Prevalence of Cardiovascular Diseases:
The World Health Organization reported that cardiovascular diseases (CVDs) account for approximately 32% of global deaths, translating to around 17.9 million fatalities annually. In future, the prevalence of CVDs is projected to rise, with an estimated 1.5 million new cases expected. This growing patient population drives the demand for drug eluting stents, as they are essential in treating blocked arteries and improving patient outcomes.
Advancements in Stent Technology:
The drug eluting stent market is witnessing rapid technological advancements, with innovations such as biodegradable polymers and improved drug formulations. For instance, the introduction of new stent designs has led to a 30% reduction in restenosis rates. In future, these advancements are expected to enhance the efficacy and safety of stent procedures, thereby increasing adoption rates among healthcare providers and patients alike.
Rising Geriatric Population:
According to the United Nations, the global population aged 65 and older is projected to reach 1.5 billion in future, with future experiencing a significant increase in its elderly demographic. This age group is particularly susceptible to cardiovascular diseases, leading to a higher demand for interventions like drug eluting stents. The growing geriatric population is thus a critical driver for market expansion in future, necessitating advanced treatment options.
Market Challenges
High Cost of Drug Eluting Stents:
The average cost of drug eluting stents can range from $1,000 to $3,000 per unit, which poses a significant financial burden on healthcare systems and patients. In future, where healthcare budgets are constrained, the high cost can limit access to these essential devices, potentially leading to suboptimal treatment outcomes for patients with cardiovascular diseases.
Stringent Regulatory Requirements:
Regulatory bodies, such as the FDA, impose rigorous approval processes for new medical devices, including drug eluting stents. In future, the average time for regulatory approval can exceed 12 months, delaying market entry for innovative products. This lengthy process can hinder the ability of manufacturers to respond swiftly to market needs and technological advancements, impacting overall market growth.
Drug Eluting Stent Market Future Outlook
The drug eluting stent market in future is poised for significant growth, driven by technological innovations and an increasing patient population. As healthcare systems adapt to the rising prevalence of cardiovascular diseases, the demand for advanced stenting solutions will likely escalate. Furthermore, the integration of digital health technologies and personalized medicine approaches will enhance patient care, leading to improved outcomes. The market is expected to evolve with a focus on patient-centric solutions and innovative partnerships among stakeholders.
Market Opportunities
Expansion in Emerging Markets:
Emerging markets in future present substantial growth opportunities for drug eluting stents, driven by increasing healthcare investments. The World Bank estimates that healthcare expenditure in these regions will rise by 10% annually, facilitating greater access to advanced medical technologies and improving patient outcomes.
Development of Bioresorbable Stents:
The market for bioresorbable stents is gaining traction, with research indicating a potential market size of $1 billion in future. These stents offer the advantage of reducing long-term complications associated with permanent implants, making them an attractive option for patients and healthcare providers in future, thus creating new avenues for growth.
Please Note: It will take 5-7 business days to complete the report upon order confirmation.
The Drug Eluting Stent market is valued at USD 8.8 billion, based on a five-year historical analysis. Growth is primarily driven by the increasing prevalence of cardiovascular diseases, advancements in stent technology such as next-generation drug coatings, and rising healthcare expenditure. The demand for drug-eluting stents is further fueled by the growing aging population, the adoption of minimally invasive procedures, and the integration of advanced materials that improve patient outcomes and reduce hospital stays .
Key players in this market are predominantly located in North America, Europe, and Asia-Pacific. The United States leads the market due to its advanced healthcare infrastructure, high prevalence of coronary artery diseases, and significant investments in medical technology. Countries such as Germany and Japan also contribute significantly, driven by robust healthcare systems, high procedure volumes, and ongoing innovation in cardiovascular treatments .
The "Premarket Approval (PMA) for Drug-Eluting Stents: Guidance for Industry and FDA Staff" issued by the U.S. Food and Drug Administration (FDA) in 2023 requires manufacturers to submit enhanced clinical data for approval. This regulation mandates comprehensive evidence of long-term safety and efficacy, including robust data on clinical outcomes and potential risks, as a prerequisite for market entry in the United States .
Drug Eluting Stent Market Segmentation
By Type:
The Drug Eluting Stent market can be segmented into Polymer-Based Drug Eluting Stents, Polymer-Free Drug Eluting Stents, Bioresorbable Stents, Bare Metal Stents, and Others. Polymer-Based Drug Eluting Stents dominate the market due to their demonstrated efficacy in reducing restenosis rates and their widespread clinical acceptance. The preference for these stents is reinforced by their ability to deliver drugs effectively, compatibility with a
oad range of patient profiles, and ongoing innovation in polymer and drug technologies .
By End-User:
The market is also segmented by end-users, including Hospitals, Specialty Clinics, Cardiac Catheterization Labs, Ambulatory Surgical Centers, and Others. Hospitals are the leading end-user segment, attributed to their comprehensive cardiac care capabilities, advanced surgical infrastructure, and the high volume of interventional cardiology procedures performed. The increasing number of percutaneous coronary interventions in hospitals, supported by skilled healthcare professionals and integrated care pathways, continues to drive demand for drug-eluting stents in this segment .
Drug Eluting Stent Market Competitive Landscape
The Drug Eluting Stent Market is characterized by a dynamic mix of regional and international players. Leading participants such as Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Johnson & Johnson (Cordis), B.
aun Melsungen AG, Terumo Corporation, Cook Medical, Cardinal Health, Inc., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Stryker Corporation, Asahi Intecc Co., Ltd., Koninklijke Philips N.V., Biotronik SE & Co. KG, Lepu Medical Technology Co., Ltd., OrbusNeich Medical Group Holdings Limited, Becton, Dickinson and Company contribute to innovation, geographic expansion, and service delivery in this space.
Abbott Laboratories
1888
Abbott Park, Illinois, USA
Boston Scientific Corporation
1979
Marlborough, Massachusetts, USA
Medtronic plc
1949
Dublin, Ireland
Johnson & Johnson (Cordis)
1886
New
unswick, New Jersey, USA
B.
aun Melsungen AG
1839
Melsungen, Germany
Company
Establishment Year
Headquarters
Group Size (Large, Medium, or Small as per industry convention)
Global Drug Eluting Stent Revenue
Revenue Growth Rate (CAGR)
Market Share (%)
Geographic Presence (Number of Countries/Regions)
Product Portfolio
eadth (Number of DES SKUs)
Drug Eluting Stent Market Industry Analysis
Growth Drivers
Increasing Prevalence of Cardiovascular Diseases:
The World Health Organization reported that cardiovascular diseases (CVDs) account for approximately 32% of global deaths, translating to around 17.9 million fatalities annually. In future, the prevalence of CVDs is projected to rise, with an estimated 1.5 million new cases expected. This growing patient population drives the demand for drug eluting stents, as they are essential in treating blocked arteries and improving patient outcomes.
Advancements in Stent Technology:
The drug eluting stent market is witnessing rapid technological advancements, with innovations such as biodegradable polymers and improved drug formulations. For instance, the introduction of new stent designs has led to a 30% reduction in restenosis rates. In future, these advancements are expected to enhance the efficacy and safety of stent procedures, thereby increasing adoption rates among healthcare providers and patients alike.
Rising Geriatric Population:
According to the United Nations, the global population aged 65 and older is projected to reach 1.5 billion in future, with future experiencing a significant increase in its elderly demographic. This age group is particularly susceptible to cardiovascular diseases, leading to a higher demand for interventions like drug eluting stents. The growing geriatric population is thus a critical driver for market expansion in future, necessitating advanced treatment options.
Market Challenges
High Cost of Drug Eluting Stents:
The average cost of drug eluting stents can range from $1,000 to $3,000 per unit, which poses a significant financial burden on healthcare systems and patients. In future, where healthcare budgets are constrained, the high cost can limit access to these essential devices, potentially leading to suboptimal treatment outcomes for patients with cardiovascular diseases.
Stringent Regulatory Requirements:
Regulatory bodies, such as the FDA, impose rigorous approval processes for new medical devices, including drug eluting stents. In future, the average time for regulatory approval can exceed 12 months, delaying market entry for innovative products. This lengthy process can hinder the ability of manufacturers to respond swiftly to market needs and technological advancements, impacting overall market growth.
Drug Eluting Stent Market Future Outlook
The drug eluting stent market in future is poised for significant growth, driven by technological innovations and an increasing patient population. As healthcare systems adapt to the rising prevalence of cardiovascular diseases, the demand for advanced stenting solutions will likely escalate. Furthermore, the integration of digital health technologies and personalized medicine approaches will enhance patient care, leading to improved outcomes. The market is expected to evolve with a focus on patient-centric solutions and innovative partnerships among stakeholders.
Market Opportunities
Expansion in Emerging Markets:
Emerging markets in future present substantial growth opportunities for drug eluting stents, driven by increasing healthcare investments. The World Bank estimates that healthcare expenditure in these regions will rise by 10% annually, facilitating greater access to advanced medical technologies and improving patient outcomes.
Development of Bioresorbable Stents:
The market for bioresorbable stents is gaining traction, with research indicating a potential market size of $1 billion in future. These stents offer the advantage of reducing long-term complications associated with permanent implants, making them an attractive option for patients and healthcare providers in future, thus creating new avenues for growth.
Please Note: It will take 5-7 business days to complete the report upon order confirmation.
Table of Contents
98 Pages
- 1. drug eluting stent size, share, growth drivers, trends, opportunities & – Market Overview
- 1.1. Definition and Scope
- 1.2. Market Taxonomy
- 1.3. Market Growth Rate
- 1.4. Market Segmentation Overview
- 2. drug eluting stent size, share, growth drivers, trends, opportunities & – Market Size (in USD Bn), 2019–2024
- 2.1. Historical Market Size
- 2.2. Year-on-Year Growth Analysis
- 2.3. Key Market Developments and Milestones
- 3. drug eluting stent size, share, growth drivers, trends, opportunities & – Market Analysis
- 3.1. Growth Drivers
- 3.1.1. Increasing prevalence of cardiovascular diseases
- 3.1.2. Advancements in stent technology
- 3.1.3. Rising geriatric population
- 3.1.4. Growing demand for minimally invasive procedures
- 3.2. Restraints
- 3.2.1. High cost of drug eluting stents
- 3.2.2. Stringent regulatory requirements
- 3.2.3. Risk of complications and adverse effects
- 3.2.4. Market saturation in developed regions
- 3.3. Opportunities
- 3.3.1. Expansion in emerging markets
- 3.3.2. Development of bioresorbable stents
- 3.3.3. Increasing healthcare expenditure
- 3.3.4. Collaborations and partnerships for innovation
- 3.4. Trends
- 3.4.1. Shift towards personalized medicine
- 3.4.2. Integration of digital health technologies
- 3.4.3. Focus on patient-centric care
- 3.4.4. Rise in outpatient procedures
- 3.5. Government Regulation
- 3.5.1. FDA approval processes for new devices
- 3.5.2. Reimbursement policies for stent procedures
- 3.5.3. Guidelines for clinical trials
- 3.5.4. Quality control standards for manufacturing
- 3.6. SWOT Analysis
- 3.7. Stakeholder Ecosystem
- 3.8. Competition Ecosystem
- 4. drug eluting stent size, share, growth drivers, trends, opportunities & – Market Segmentation, 2024
- 4.1. By Type (in Value %)
- 4.1.1. Polymer-Based Drug Eluting Stents
- 4.1.2. Polymer-Free Drug Eluting Stents
- 4.1.3. Bioresorbable Stents
- 4.1.4. Bare Metal Stents
- 4.1.5. Others
- 4.2. By End-User (in Value %)
- 4.2.1. Hospitals
- 4.2.2. Specialty Clinics
- 4.2.3. Cardiac Catheterization Labs
- 4.2.4. Ambulatory Surgical Centers
- 4.2.5. Others
- 4.3. By Distribution Channel (in Value %)
- 4.3.1. Direct Sales
- 4.3.2. Distributors
- 4.3.3. Online Sales
- 4.4. By Material (in Value %)
- 4.4.1. Cobalt-Chromium
- 4.4.2. Platinum-Chromium
- 4.4.3. Stainless Steel
- 4.4.4. Nitinol
- 4.4.5. Biodegradable Materials
- 4.4.6. Others
- 4.5. By Drug Type (in Value %)
- 4.5.1. Sirolimus
- 4.5.2. Paclitaxel
- 4.5.3. Everolimus
- 4.5.4. Zotarolimus
- 4.5.5. Biolimus
- 4.5.6. Others
- 4.6. By Region (in Value %)
- 4.6.1. North America
- 4.6.2. Europe
- 4.6.3. Asia-Pacific
- 4.6.4. Latin America
- 4.6.5. Middle East & Africa
- 4.6.6. Others
- 5. drug eluting stent size, share, growth drivers, trends, opportunities & – Market Cross Comparison
- 5.1. Detailed Profiles of Major Companies
- 5.1.1. Abbott Laboratories
- 5.1.2. Boston Scientific Corporation
- 5.1.3. Medtronic plc
- 5.1.4. Johnson & Johnson (Cordis)
- 5.1.5. B. Braun Melsungen AG
- 5.2. Cross Comparison Parameters
- 5.2.1. Global Drug Eluting Stent Revenue
- 5.2.2. Revenue Growth Rate (CAGR)
- 5.2.3. Market Share (%)
- 5.2.4. Geographic Presence (Number of Countries/Regions)
- 5.2.5. R&D Investment (USD or % of Revenue)
- 6. drug eluting stent size, share, growth drivers, trends, opportunities & – Market Regulatory Framework
- 6.1. FDA Compliance Standards
- 6.2. Compliance Requirements and Audits
- 6.3. Certification Processes
- 7. drug eluting stent size, share, growth drivers, trends, opportunities & – Market Future Size (in USD Bn), 2025–2030
- 7.1. Future Market Size Projections
- 7.2. Key Factors Driving Future Market Growth
- 8. drug eluting stent size, share, growth drivers, trends, opportunities & – Market Future Segmentation, 2030
- 8.1. By Type (in Value %)
- 8.2. By End-User (in Value %)
- 8.3. By Distribution Channel (in Value %)
- 8.4. By Material (in Value %)
- 8.5. By Drug Type (in Value %)
- 8.6. By Region (in Value %)
- Disclaimer
- Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
